10 results
Th**is study will compare sequential mifepristone and misoprostol (*M&M*) treatment versus misoprostol treatment alone, which is currently the standard medical treatment in the Netherlands.
To evaluate the benefit of Misoprostol prior to hysteroscopy in nulliparous and postmenopausal women regarding the reduction of pain
To investigate whether Misoprostol (compared to placebo) will diminish the amount of insertion failures. To investigate whether Misoprostol (compared to placebo) will diminish the amount of insertion related complications (eg. syncope, perforation…
To assess the effectiveness of misoprostol in the management of retained placenta. Will 800 micrograms of misoprostol orally reduce the need for manual removal under general anaesthesia and prove to be a safe alternative?
To assess non-inferiority of a regimen containing ritonavir-boosted elvitegravir versusraltegravir, each administered with a background regimen in HIV-1 infected,antiretroviral treatment-experienced adult subjects as determined by the proportion…
Primary: Antiviral efficacy after 48 weeks of treatment. Secundary: Antiviral efficacy after 24 weeks, safety and tolerability, resistance development, PK, incidence of HIV-associated conditions, gender-, race-, and/or HIV-1 subtype on response to…
This study will compare sequential mifepristone and misoprostol treatment versus misoprostol treatment alone, which is currently the standard medical treatment in the Netherlands.
Primary: superiority of dabrafenib and trametinib combination therapy over dabrafenib and trametinib-placebo (dabrafenib monotherapy) with respect to progression-free survival (PFS) for subjects with advanced/metastatic BRAF V600E/K mutation-…
* Safety Run inTo determine the recommended regimen of PDR001 in combination with dabrafenib and trametinib for the randomized part (part 3)* Biomarker cohortTo evaluate changes in the immune microenvironment and biomarker modulations upon treatment…
Primary: efficacy of dabrafenib and trametinib combination therapy compared to placebo with respect to relapse-free survival in patients with completely resected, histologically confirmed, BRAF V600E/K high risk, stage III cutaneous melanoma.…